May & Baker Nigeria Plc led the pharmaceutical sector in profitability for the first half of 2026, achieving a net profit margin of 16.59 percent. While the combined profit margin for five major listed pharma firms rose to 10.24 percent, May & Baker’s performance was distinct because it stemmed from improved cost efficiency rather than top-line revenue growth. Fidson Healthcare followed with a 10.37 percent margin, while MeCure Industries and Neimeth International Pharmaceuticals recorded 7.76 percent and 5.65 percent respectively. Morison Industries trailed the group, posting a net loss for the period.